More MS news articles for May 2002

Differential intracellular expression of CCR5 and chemokines in multiple sclerosis subtypes

J Neurol 2002 May;249(5):576-83
Jalonen TO, Pulkkinen K, Ukkonen M, Saarela M, Elovaara I.
Medical School, University of Tampere.

Chemokines are small chemoattractant cytokines which participate in the migration of immune cells into the CNS and contribute to the T cell-mediated pathogenesis of multiple sclerosis (MS).

The expression of chemokines and their receptors in freshly isolated mononuclear cells from peripheral blood (PBMC) was studied in relation to MS subtype, disease duration and progression in a total of 57 patients with MS (22 relapsing remitting, RRMS; 21 secondary progressive, SPMS; 14 primary progressive, PPMS) and 17 healthy controls.

The RNA expression of CCR5 in PBMC was analysed by reverse transcription polymerase chain reaction (RT-PCR) using specific oligonucleotide primers.

The PBMC levels of CCR5-ligands MIP-1alpha/beta and RANTES, and chemokines MCP-1, IL-8, lymphotactin, IP-10 and I-309 were analysed by ribonuclease protection assay (RPA).

Significantly increased intracellular CCR5 RNA expression intensity was detected in PPMS when compared with SPMS ( p=0.009), RRMS ( p=0.013), and controls ( p=0.023).

However, the surface expression of CCR5 on CD4(+) cells from PBMC, analysed by flow cytometry, appeared to be similar in all MS subtypes and controls.

The CCR5-ligands RANTES and MIP-1b were expressed constitutively in all patients and controls.

Interleukin-8 was found in all MS subtypes and controls, but IP-10 was detected only in RRMS and SPMS, and lymphotactin occasionally in other subtypes but PPMS.

MCP-1, MIP-1a or I-309 were not expressed in any of the groups studied.

A correlation was found between the RNA levels of RANTES and CCR5 in PPMS ( r=0.735).

Differential profile in the expression of CCR5 and chemokines between PPMS and other MS subtypes may contribute to differences in the pathogenesis of MS and thus can be of importance in the development of new treatments for MS.